サンプル依頼リスト カート
  • English
  • Korean
表紙：バレット食道治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374805

バレット食道治療の世界市場-2023年～2030年

Global Barett's Esophagus Treatment Market -2023-2030

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
バレット食道治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

バレット食道は、食道（口と胃をつなぐ食物/嚥下管）の正常な層状扁平上皮（ピンク色の内壁または粘膜）が酸の逆流によって傷害され、肥厚・発赤した状態です。内視鏡検査で検出され、病理学的には腸管形質転換柱状上皮（腸に存在するような厚い細胞の存在）の存在によって確認されます。

GERDは、食道と胃の間に存在し、胃内容物の食道への逆流を防ぐ重要な弁である下部食道括約筋（LES）を通して、胃酸と胆汁が逆流してくる疾患です。胃の内壁は消化に必要な酸性環境に対応できる粘液性の柱状上皮でできているのに対し、食道の内壁は扁平上皮でできています。

市場促進要因：市場抑制要因

胃食道逆流症（GERD）有病率の上昇

胃食道逆流症の有病率の上昇は、予測期間中の市場成長を促進する要因の一つです。GERDの有病率は世界的にばらつきがあり、南米で23％、北米で18％～28％、オーストラリアで12％、東アジアで2％～7％、欧州で9％～26％、中東で9％～33％と推定されています。サウジアラビアにおけるGERD有病率は29～45％でした。サウジアラビアのGERD有病率は欧米諸国や東アジア諸国と比較してかなり高いです。

さらに、治療法の技術的進歩、人々のライフスタイルの変化、ヘルスケアインフラへの投資の増加、老人人口の増加、研究開発の増加などが、予測期間中の市場成長をさらに後押しすることになるでしょう。

市場力学：抑制要因

疾患に伴う合併症は、市場成長を阻害する主要な抑制要因の1つです。バレット食道の患者は食道がんになる可能性が高いです。食道細胞が前がん変化を起こしている患者であっても、その危険性は少ないです。幸いなことに、バレット食道の患者に食道がんが発生することはめったにないです。また、認知度の低さ、治療費の高さ、診断の課題、限られた治療オプションなども予測期間中の市場成長を阻害する要因です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 胃食道逆流症（GERD）の有病率の上昇
      • 治療オプションにおける技術進歩の高まり
    • 抑制要因
      • 疾患に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 低悪性度異形成
  • 高悪性度異形成
  • 異形成なし

第8章 治療タイプ別

  • 内視鏡的切除
  • ラジオ波焼灼術
  • 食道切除術
  • 光線力学的療法
  • 凍結療法

第9章 薬物療法

  • 制酸剤
  • プロテインポンプ阻害薬
  • ヒスタミン遮断薬
  • 運動促進剤

第10章 販売チャネル別

  • エンドユーザー
  • 流通チャネル

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Advacarepharma
  • Apotex
  • Takeda Pharmaceutical Company Limited
  • Woodward Pharma Services LLC
  • Steris
  • Medtronic Plc
  • Stryker
  • Boston Scientific
  • Olympus

第14章 付録

目次
Product Code: PH7242

Overview

Barrett's esophagus is a condition in which the normal stratified squamous epithelium (pink lining or mucosal lining) of the oesophagus (food/swallowing pipe that connects mouth and stomach) is damaged by acid reflux and thickens and reddens, as detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia columnar epithelium (the presence of thick cells similar to those present in the intestine).

GERD is a condition, where the acid and bile from the stomach come back up through the lower oesophageal sphincter (LES), a critically important valve, present between the oesophagus and the stomach that prevents the reflux of gastric contents back into the oesophagus. The lining of the stomach is made of mucinous columnar epithelium, which can handle the acidic environment needed for digestion, whereas the lining of the oesophagus, on the other hand, is made of squamous epithelium.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of gastroesophageal reflux disease (GERD)

The rise in the prevalence of gastroesophageal reflux diseases is one of the factors that drive the market growth during the forecast period. The prevalence of GERD is varied globally, which is estimated to be 23% in South America, 18% to 28% in North America, 12% in Australia, 2% to 7% in East Asia, 9% to 26% in Europe, and 9% to 33% in the Middle East the evidence suggests that the prevalence of GERD has significantly increased since 1995, especially in East Asia and North America. The prevalence of GERD in Saudi Arabia varied from 29% to 45%. In the Saudi population, the prevalence of GERD is substantially higher compared to western countries and East Asian countries.

Furthermore, technological advancements in treatments, changing lifestyles of people, increasing investment in healthcare infrastructure, rise in the number of geriatric populations, increasing research and developments and other will further drive the market growth further during the forecast period.

Market Dynamics: Restraint

Complications associated with the disease is one of the major restraining factors that hampers the market growth. Those who have barrett's esophagus are more likely to get esophageal cancer. Even in patients whose esophageal cells have undergone precancerous alterations, the danger is minimal. Fortunately, esophageal cancer seldom occurs in patients with barrett's esophagus. Also, lack of awareness, high cost of treatment, diagnostic challenges, limited treatment options and others will also be the restraint factors that hamper the market growth during the forecast period.

Segment Analysis

The global barett's esophagus treatment is segmented based on type, treatment, medication, sales channel and region.

The low-grade dysplasia from the type segment accounted for approximately 41.2% of the market share

The low-grade dysplasia from the type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Low-grade dysplasia means that some of the cells look abnormal. These cells may look like cancer cells in some ways, but unlike cancer, they don't have the ability to spread to other parts of your body. This is a very early pre-cancer of the esophagus.

For instance, in August 2023, Castle Biosciences, Inc. a company improving health through innovative tests that guide patient care, stated a new study published in The American Journal of Gastroenterology showing how use of tissuecypher barrett's esophagus test results can significantly improve management decisions for barrett's esophagus patients with low-grade dysplasia (LGD) to improve health outcomes.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. As the population continues to age, the demand for treatment for Barrett's esophagus with dysplasia is expected to increase. Due to this, there have been significant advancements in endoscopic technologies and treatments for barrett's esophagus with dysplasia in North America, including radiofrequency ablation (RFA), cryotherapy, and endoscopic mucosal resection (EMR).

Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. For instance, in August 2023, esophageal and stomach cancer rates have increased significantly in the US and other western countries over the past five decades.

Esophageal adenocarcinoma and GCA are highly fatal cancers. However, research scientist Joel Rubenstein suggests that preventative measures can help. Screening can identify pre-cancerous changes in patients, such as barrett's esophagus, which can be diagnosed in those with long-term gastroesophageal reflux disease (GERD).

COVID-19 Impact Analysis

The COVID-19 pandemic has dramatically impacted gastroenterology services worldwide. As coronavirus infection rates rose, many professional bodies advised that all endoscopy, except emergency and essential procedures, be stopped immediately. Upper gastrointestinal endoscopy was considered a high-risk procedure due to a greater potential for aerosolization and transmission of the SARS-CoV-2 virus .

Competitive Landscape

The major global players in the barett's esophagus treatment market include: Novartis AG, Advacarepharma, Apotex, Takeda Pharmaceutical Company Limited, Woodward Pharma Services LLC,Steris, Medtronic Plc, Stryker, Boston Scientific, Olympus and among others.

Key Developments

  • In August 2022, the American College of Gastroenterology released new guidelines for Barrett's esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett's esophagus, and implementing volume criteria for endoscopic therapy centres.
  • In January 2022, Researchers unmask the cellular source of barrett's esophagus. Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of barrett's esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.
  • In June 2020, Cernostics stated blinded, independent validation of tissuecypher performance for predicting risk of progression to esophageal cancer in patients with non-dysplastic be.

Why Purchase the Report?

  • To visualize the global barett's esophagus treatment market segmentation-based type, treatment, medication, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of barett's esophagus treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global barett's esophagus treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Medication
  • 3.4. Snippet by Sales Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the prevalence of gastroesophageal reflux disease (GERD)
      • 4.1.1.2. Rise in the technology advancements in treatment options
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the disease
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Low Grade Dysplasia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. High-Grade Dysplasia
  • 7.4. No Dysplasia

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Endoscopic Resection*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Radiofrequency Ablation
  • 8.4. Esophagectomy
  • 8.5. Photodynamic Therapy
  • 8.6. Cryotherapy

9. By Medication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Antacids*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Protein Pump Inhibitors
  • 9.4. Histamine Blockers
  • 9.5. Prokinetic Agents

10. By Sales Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.1.2. Market Attractiveness Index, By Sales Channel
  • 10.2. End User*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Distribution Channel

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis AG
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Advacarepharma
  • 13.3. Apotex
  • 13.4. Takeda Pharmaceutical Company Limited
  • 13.5. Woodward Pharma Services LLC
  • 13.6. Steris
  • 13.7. Medtronic Plc
  • 13.8. Stryker
  • 13.9. Boston Scientific
  • 13.10. Olympus

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us